Skip to main content
. Author manuscript; available in PMC: 2022 Oct 13.
Published in final edited form as: Sci Immunol. 2022 Oct 28;7(76):eabp9962. doi: 10.1126/sciimmunol.abp9962

Fig. 2. SW186 has broad neutralizing activity against SARS-CoV-2 variants of concern.

Fig. 2.

(A) The kinetics of binding of SW186 to the spike protein using BioLayer Interferometry (BLI). The biotinylated S-ecto protein was loaded on the streptavidin sensor and then SW186 was applied at indicated concentrations. The KD value is mean ± SD, n=3. (B) Neutralization assays were performed using pseudotyped viruses displaying the spike protein from indicated SARS-CoV-2 variants. The values are mean ± SD, n=3. (C-E) Neutralization assays were performed using recombinant infectious SARS-CoV-2 viruses as indicated. The values are mean ± SD, n=2. (F) Neutralization assays of SW186 and S309 against the SARS-CoV-1-D28 (deletion of C-terminal 28aa) pseudotyped virus. Each antibody dilution was done in duplicates. (G) The neutralization activities (IC50 at ng/mL) of monoclonal antibodies against SARS-CoV-2 variants were adapted from Fig. 2C–D and published studies(4–6). The heatmap shows the IC50 value.